跳至主要内容
临床试验/JPRN-UMIN000044811
JPRN-UMIN000044811招募中未知

Prospective observation study for the efficacy and safety of combined therapy with Ipilimumab and Nivolumab in non-small cell lung cancer patients - Prospective observation study for the efficacy and safety of combined therapy with Ipilimumab and Nivolumab in non-small cell lung cancer patients

Kyoto Prefectural University of Medicine0 个研究点目标入组 50 人开始时间: 2021年7月9日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 100years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • (1) Patients with active multiple cancers (hormonal therapy for prostate cancer and breast cancer is acceptable) (2)Patients with a history of treatment with systemic chemotherapy or immune checkpoint inhibitors (However, molecularly targeted cancer drugs for patients with positive driver gene mutations and postoperative adjuvant chemotherapy for patients with postoperative recurrence are acceptable) (3)Other patients who are judged inappropriate by the physician in charge.

研究者

相似试验